Nucleoside (Acid) Analogues Treatment in Patients With Normal ALT and Positive HBVDNA.

Recruiting now · Not applicable

Conditions studied: Hepatitis B Virus

In brief

This study is to investigate the clinical efficacy and safety of Nucleoside (acid) analogues treatment in patients with normal Alanine Aminotransferase and positive Hepatitis B virus DNA.

Key facts

Study ID

NCT04231565

Run by

Third Affiliated Hospital, Sun Yat-Sen University

People needed

200

Starts

2020-06-04

Expected to finish

2027-07-01

Last updated by the study team

2024-03-01

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Positive hepatitis b surface antigen and hepatitis b antibody > 0.5 year;
• Age from 18 to 65 years old;
• Serum Alanine Aminotransferase(ALT) ≤1×ULN at least 12 weeks;
• Positive Hepatitis b virus(HBV);
• Do not receive nucleotide/nucleoside analogues or interferon treatment in the past half year.

You may not qualify if…

• Other active liver diseases;
• Hepatocellular carcinoma or other malignancy;
• Pregnancy or lactation;
• Human immunodeficiency virus infection or congenital immune deficiency diseases; 5.Severe diabetes, autoimmune diseases; 6.Other important organ dysfunctions; 7.Using glucocorticoid; 8.Patients can not follow-up; 9.Investigator considering inappropriate.

Where it is running

• Third Affiliated Hospital of Sun Yat-sen University — Guangzhou, Guangdong, China (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.